ULBP3 and neoplasm: Intriguingly, the addition of an anti-ULBP3 antibody prepared in our laboratory triggered ULBP3-mediated ADCC and increased NK cytotoxicity against ULBP3-expressing tumor cells, suggesting the antibody has immunotherapeutic value for cancer treatment.